Jan Friedrich Scheitz

Jan Friedrich Scheitz

Auto-generated profile, based on publicly available information

Jan Friedrich Scheitz

Department of Neurology with Experimental Neurology and Center for Stroke Research Berlin, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
JSJan F Scheitz
Jan F Scheitz
CNChristian H Nolte
Christian H Nolte
WDWolfram Doehner
Wolfram Doehner
VHVladimir Hachinski
Vladimir Hachinski
MEMatthias Endres
Matthias Endres

3 September 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JSJan F. Scheitz
Jan F. Scheitz
LSLuciano A. Sposato
Luciano A. Sposato
JSJeanette Schulz‐Menger
Jeanette Schulz‐Menger
CNChristian H. Nolte
Christian H. Nolte
JBJohannes Backs
Johannes Backs
MEMatthias Endres
Matthias Endres
After ischemic stroke, there is a significant burden of cardiovascular complications, both in the acute and chronic phase. Severe adverse cardiac events occur in 10% to 20% of patients within the first few days after stroke and comprise a continuum of cardiac changes ranging from acute myocardial injury and coronary syndromes to heart failure or arrhythmia. Recently, the term stroke–heart syndrome was introduced to provide an integrated conceptual framework that summarizes neurocardiogenic mechanisms that lead to these cardiac events after stroke. New findings from experimental and clinical studies have further refined our understanding of the clinical manifestations, pathophysiology, and potential long‐term consequences of the stroke–heart syndrome. Local cerebral and systemic mediators, which mainly involve autonomic dysfunction and increased inflammation, may lead to altered cardiomyocyte metabolism, dysregulation of (tissue‐resident) leukocyte populations, and (micro‐) vascular changes. However, at the individual patient level, it remains challenging to differentiate between comorbid cardiovascular conditions and stroke‐induced heart injury. Therefore, further research activities led by joint teams of basic and clinical researchers with backgrounds in both cardiology and neurology are needed to identify the most relevant therapeutic targets that can be tested in clinical trials.

1 June 2016 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
Georgios TsivgoulisGeorgios Tsivgoulis
Georgios Tsivgoulis
Ramin ZandRamin Zand
Ramin Zand
AKAristeidis H. Katsanos
Aristeidis H. Katsanos
GTGuillaume Turc
Guillaume Turc
CNChristian H. Nolte
Christian H. Nolte
AAAndrei V. Alexandrov
Andrei V. Alexandrov
Cerebral microbleeds (CMBs) as visualized on gradient echo T2* or susceptibility-weighted magnetic resonance imaging (MRI) are considered markers of bleeding-prone cerebral vessel microangiopathies and constitute both significant and independent predictors of future cerebral bleeding.1-3 Several clinical studies have associated CMB presence with hemorrhagic stroke and hemorrhagic complications following antithrombotic medications.4

2 March 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
TKThomas Krause
Thomas Krause
KWKathrin Werner
Kathrin Werner
JFJochen B. Fiebach
Jochen B. Fiebach
KVKersten Villringer
Kersten Villringer
SPSophie K. Piper
Sophie K. Piper
CNChristian H. Nolte
Christian H. Nolte

1 August 2017 in Stroke
Verified
Journal Article
Closed access
ACAndreas Charidimou
Andreas Charidimou
GTGuillaume Turc
Guillaume Turc
COCatherine Oppenheim
Catherine Oppenheim
SYShenqiang Yan
Shenqiang Yan
JSJan F. Scheitz
Jan F. Scheitz
DWDavid J. Werring
David J. Werring
Background and Purpose—: We assessed whether the presence, number, and distribution of cerebral microbleeds (CMBs) on pre-intravenous thrombolysis MRI scans of acute ischemic stroke patients are associated with an increased risk of intracerebral hemorrhage (ICH) or poor functional outcome. Methods—: We performed an individual patient data meta-analysis, including prospective and retrospective studies of acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Using multilevel mixed-effects logistic regression, we investigated associations of pre-treatment CMB presence, burden (1, 2–4, ≥5, and >10), and presumed pathogenesis (cerebral amyloid angiopathy defined as strictly lobar CMBs and noncerebral amyloid angiopathy) with symptomatic ICH, parenchymal hematoma (within [parenchymal hemorrhage, PH] and remote from the ischemic area [remote parenchymal hemorrhage, PHr]), and poor 3- to 6-month functional outcome (modified Rankin score >2). Results—: In 1973 patients from 8 centers, the crude prevalence of CMBs was 526 of 1973 (26.7%). A total of 77 of 1973 (3.9%) patients experienced symptomatic ICH, 210 of 1806 (11.6%) experienced PH, and 56 of 1720 (3.3%) experienced PHr. In adjusted analyses, patients with CMBs (compared with those without CMBs) had increased risk of PH (odds ratio: 1.50; 95% confidence interval: 1.09–2.07; P =0.013) and PHr (odds ratio: 3.04; 95% confidence interval: 1.73–5.35; P <0.001) but not symptomatic ICH. Both cerebral amyloid angiopathy and noncerebral amyloid angiopathy patterns of CMBs were associated with PH and PHr. Increasing CMB burden category was associated with the risk of symptomatic ICH ( P =0.014), PH ( P =0.013), and PHr ( P 10 CMBs independently predicted poor 3- to 6-month outcome (odds ratio: 1.85; 95% confidence interval: 1.10–3.12; P =0.020; and odds ratio: 3.99; 95% confidence interval: 1.55–10.22; P =0.004, respectively). Conclusions—: Increasing CMB burden is associated with increased risk of ICH (including PHr) and poor 3- to 6-month functional outcome after intravenous thrombolysis for acute ischemic stroke.

1 February 2017 in Stroke
Verified
Journal Article
Closed access
PDF file
JSJan F. Scheitz
Jan F. Scheitz
AAAzmil H. Abdul-Rahim
Azmil H. Abdul-Rahim
RMRachael L. MacIsaac
Rachael L. MacIsaac
CCCharith Cooray
Charith Cooray
HSHeidi Sucharew
Heidi Sucharew
KLKennedy R. Lees
Kennedy R. Lees
Background and Purpose—: The National Institutes of Health Stroke Scale (NIHSS) correlates with presence of large anterior vessel occlusion (LAVO). However, the application of the full NIHSS in the prehospital setting to select patients eligible for treatment with thrombectomy is limited. Therefore, we aimed to evaluate the prognostic value of simple clinical selection strategies. Methods—: Data from the Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Registry (January 2012–May 2014) were analyzed retrospectively. Patients with complete breakdown of NIHSS scores and documented vessel status were included. We assessed the association of prehospital stroke scales and NIHSS symptom profiles with LAVO (internal carotid artery, carotid-terminus or M1-segment of the middle cerebral artery). Results—: Among 3505 patients, 23.6% (n=827) had LAVO. Pathological finding on the NIHSS item best gaze was strongly associated with LAVO (adjusted odds ratio 4.5, 95% confidence interval 3.8–5.3). All 3 face–arm–speech–time test (FAST) items identified LAVO with high sensitivity. Addition of the item best gaze to the original FAST score (G-FAST) or high scores on other simplified stroke scales increased specificity. The NIHSS symptom profiles representing total anterior syndromes showed a 10-fold increased likelihood for LAVO compared with a nonspecific clinical profile. If compared with an NIHSS threshold of ≥6, the prehospital stroke scales performed similarly or even better without losing sensitivity. Conclusions—: Simple modification of the face–arm–speech–time score or evaluating the NIHSS symptom profile may help to stratify patients’ risk of LAVO and to identify individuals who deserve rapid transfer to comprehensive stroke centers. Prospective validation in the prehospital setting is required.